BioLargo CSO and director reports locked-up stock compensation
Rhea-AI Filing Summary
BioLargo, Inc. (BLGO) reported an insider stock acquisition by a director and Chief Science Officer on a Form 4. On 11/14/2025, the reporting person acquired 313,754 shares of common stock at $0.16 per share through an exchange for accrued salary and unreimbursed business expenses. After this transaction, the insider beneficially owns 25,751,505 common shares, including 22,139,012 shares held indirectly through a wholly owned corporation.
The newly issued shares are subject to a lock-up agreement. They cannot be sold until BioLargo reports at least $40 million in gross revenue for any consolidated reporting period, or its market capitalization exceeds $300 million, or there is a change in control of the company.
Positive
- None.
Negative
- None.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock | 313,754 | $0.16 | $50K |
Footnotes (3)
- F1. The shares issued are subject to a Lock-Up Agreement dated as of the issuance date whereby shares are locked-up and restricted from sale until the Issuer reports gross revenue of at least $40 million on a consolidated basis for any reported period (e.g, quarter or annual), or the Issuer's market capitalization exceeds $300 million, or there is a "change in control" in the Issuer.
- F2. Shares received from Issuer in exchange for a reduction in amounts owed by Issuer to Reporting Person for salary and unreimbursed business expenses (equal to the product of the number of shares and acquisition price per share).
- F3. Aggregate total shares includes 22,139,012 shares owned indirectly by Reporting Person through a wholly owned corporation.
AI-generated analysis. How Rhea-AI works. Not financial advice.